ACURX Pharmaceuticals Raises $1.1M Amid Phase 2b Success

Introduction to ACURX PHARMACEUTICALS INC

ACURX PHARMACEUTICALS INC (NASDAQ: ACXP) is a publicly held, clinical stage biopharmaceutical company headquartered in Staten Island, New York. The company is developing a new class of small-molecule antibiotics targeting Gram-positive bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration. ACURX’s lead candidate, ibezapolstat, is currently preparing to enter Phase 3 trials for Clostridioides difficile infection, along with additional programs addressing Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE), and other difficult-to-treat infections.

Corporate Structure and Leadership

According to its LinkedIn profile, ACURX employs between 11 and 50 staff. Key executives include:

• David P. Luci, President and Chief Executive Officer, co-founder with prior leadership roles at Dipexium Pharmaceuticals and Bioenvision, Inc.
• Robert J. DeLuccia, Executive Chairman, co-founder with prior experience at Dipexium Pharmaceuticals, MacroChem, and Immunomedics, Inc.
• Robert G. Shawah, Chief Financial Officer, co-founder and former Chief Accounting Officer at Dipexium Pharmaceuticals.

The company has in-house research capabilities and collaborates with external partners for clinical development and regulatory affairs.

Recent Developments and News

• On March 10, 2025, ACURX closed a registered direct offering of 2,745,000 common shares at $0.40 per share, raising gross proceeds of approximately $1.1 million (before fees). Unregistered short-term warrants for up to 8,235,000 shares were issued concurrently.
• The SEC declared effective ACURX’s Form S-1 registration statement on May 29, 2025, enabling future public or private capital raises. On the same date, the company filed a 424B3 prospectus for the resale of up to 10,899,258 shares by Lincoln Park Capital under a purchase agreement dated May 8, 2025.
• ACURX disclosed $20,000 in lobbying expenditures for Q1 2025 focused on Department of Defense and Health and Human Services appropriations related to biodefense preparedness and antibiotic research.
• Insider activity over the past six months includes six purchases totaling approximately $160,000 across six executives. Hedge funds such as Vanguard Capital Wealth Advisors and Morgan Stanley increased their positions during Q1 2025 and Q4 2024.
• In May 2025, The Lancet Microbe published Phase 2b data on ibezapolstat, indicating a 94 percent clinical cure rate and 0 percent recurrence at one month compared to 14 percent with vancomycin. The study noted preservation and restoration of the gut microbiome. The candidate is acknowledged for holding FDA Fast-Track, QIDP, and EMA SME designations.

Financial and Strategic Analysis

As of June 18, 2025, ACXP shares closed at $0.6140, down 25.19 percent on volume of 1,189,164. Key metrics include:

• Market Capitalization: $19.27 million
• Enterprise Value: $14.63 million
• Trailing P/E: N/A (negative earnings)
• EPS (TTM): –0.70
• Total Cash (MRQ): $4.64 million
• Levered Free Cash Flow (TTM): –$4.87 million
• Net Income (TTM): –$11.87 million

The company remains pre-revenue. Its cash runway is supported by the March direct offering, and the effectiveness of the S-1 registration statement along with the Lincoln Park equity facility provide mechanisms for future financing. R&D spending is directed towards advancing ibezapolstat into global Phase 3 studies and developing products for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and anthrax biodefense.

Market Position and Industry Context

Antibiotic resistance is a notable public health concern, with Clostridioides difficile responsible for a significant number of infections in the United States annually. Standard therapies, including fidaxomicin and vancomycin, face challenges such as recurrent disease and reduced susceptibility. ACURX's Gram-positive selective spectrum (GPSS®) inhibitors target DNA polymerase IIIC, providing a different mechanism of action compared to existing treatments. Regulatory designations such as Fast-Track, QIDP, and SME underscore the medical need for effective therapies. Scientific collaborations, including presentations at the FASEB 2025 conference, support the company's initiatives to characterize its drug mechanism and promote future developments in antimicrobial solutions.

tl;dr

• June 18, 2025: ACXP shares fell 25.19 percent to $0.6140 on heightened trading.
• May 29, 2025: SEC declared ACURX’s S-1 effective and filed a prospectus for resale of up to 10.9 million shares through Lincoln Park Capital.
• March 10, 2025: The company raised $1.1 million via a registered direct offering and concurrent warrant issuance.
• May 2025: Phase 2b data for ibezapolstat published in The Lancet Microbe showed a 94 percent cure rate and no recurrences at one month versus 14 percent with vancomycin; product is Phase 3-ready with FDA Fast-Track, QIDP, and EMA SME designations.
• Cash reserves of $4.64 million and equity facilities support planned international Phase 3 trials set to begin in 2025.